Literature DB >> 20809217

Value of PET-FDG in primary breast cancer based on histopathological and immunohistochemical prognostic factors.

Pierre Heudel1, Sebastien Cimarelli, Anthony Montella, Catherine Bouteille, Thomas Mognetti.   

Abstract

BACKGROUND: The aim of the study was to analyze in breast tumors the correlation between [(18)F]fluorodeoxyglucose (FDG) uptake assessed by positron emission tomography (PET) and histopathological and immunohistochemical prognostic factors.
METHODS: FDG-PET combined with computed tomography (CT) was performed before surgery in 45 women with biopsy-proven primary breast cancer. The standardized uptake value (SUV) was compared with histopathological findings after surgery.
RESULTS: A positive relationship was found between SUV and histological grade (p < 0.0001), histological type (p = 0.001), tumor size (p < 0.0435), estrogen receptor status (p < 0.0005), and progesterone receptor status (p = 0.002). FDG-PET/CT revealed unknown distant metastatic lesions in 2 of 12 patients with triple-negative breast cancer. The sensitivity of FDG-PET/CT for detecting axillary lymph node metastases was, respectively, 21% and 100% for pN1 and pN2 cases, whereas specificity was 100% for pN0.
CONCLUSION: SUV, a preoperative and noninvasive metabolic parameter, correlates with other known prognostic factors in breast cancer. This study provides valuable insight into the usefulness of FDG-PET/CT for preoperative staging of patients with triple-negative and poorly differentiated breast tumors but not for evaluating axillary lymph nodes and lobular carcinomas.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20809217     DOI: 10.1007/s10147-010-0120-3

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  22 in total

1.  Breast imaging with fluorine-18-FDG PET: quantitative image analysis.

Authors:  N Avril; S Bense; S I Ziegler; J Dose; W Weber; C Laubenbacher; W Römer; F Jänicke; M Schwaiger
Journal:  J Nucl Med       Date:  1997-08       Impact factor: 10.057

2.  Glucose metabolism of breast cancer assessed by 18F-FDG PET: histologic and immunohistochemical tissue analysis.

Authors:  N Avril; M Menzel; J Dose; M Schelling; W Weber; F Jänicke; W Nathrath; M Schwaiger
Journal:  J Nucl Med       Date:  2001-01       Impact factor: 10.057

3.  Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations.

Authors:  N Avril; C A Rosé; M Schelling; J Dose; W Kuhn; S Bense; W Weber; S Ziegler; H Graeff; M Schwaiger
Journal:  J Clin Oncol       Date:  2000-10-15       Impact factor: 44.544

4.  A comparative study on the value of FDG-PET and sentinel node biopsy to identify occult axillary metastases.

Authors:  U Veronesi; C De Cicco; V E Galimberti; J R Fernandez; N Rotmensz; G Viale; G Spano; A Luini; M Intra; P Veronesi; A Berrettini; G Paganelli
Journal:  Ann Oncol       Date:  2006-12-12       Impact factor: 32.976

5.  Utility of PET in Breast Cancer.

Authors:  Norbert Avril; Marcus Schelling; Jorg Dose; Wolfgang A. Weber; Markus Schwaiger
Journal:  Clin Positron Imaging       Date:  1999-10

6.  Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.

Authors:  Sandip Basu; Wengen Chen; Julia Tchou; Ayse Mavi; Tevfik Cermik; Brian Czerniecki; Mitchell Schnall; Abass Alavi
Journal:  Cancer       Date:  2008-03-01       Impact factor: 6.860

7.  Predicting the prognoses of breast carcinoma patients with positron emission tomography using 2-deoxy-2-fluoro[18F]-D-glucose.

Authors:  M Oshida; K Uno; M Suzuki; T Nagashima; H Hashimoto; H Yagata; T Shishikura; K Imazeki; N Nakajima
Journal:  Cancer       Date:  1998-06-01       Impact factor: 6.860

8.  Diagnostic value of full-dose FDG PET/CT for axillary lymph node staging in breast cancer patients.

Authors:  Till A Heusner; Sherko Kuemmel; Steffen Hahn; Angela Koeninger; Friedrich Otterbach; Monia E Hamami; Klaus R Kimmig; Michael Forsting; Andreas Bockisch; Gerald Antoch; Alexander Stahl
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-05-05       Impact factor: 9.236

9.  Selective Sentinel Node Plus Additional Non-Sentinel Node Biopsy Based on an FDG-PET/CT Scan in Early Breast Cancer Patients: Single Institutional Experience.

Authors:  Jeryong Kim; Jinsun Lee; Eilsung Chang; Seongmin Kim; Kwangsun Suh; Jiyoung Sul; Insang Song; Yonghoon Kim; Chuljoo Lee
Journal:  World J Surg       Date:  2009-05       Impact factor: 3.352

10.  Preoperative evaluation of prognosis in breast cancer patients by [(18)F]2-Deoxy-2-fluoro-D-glucose-positron emission tomography.

Authors:  Tomoo Inoue; Kenji Yutani; Tetsuya Taguchi; Yasuhiro Tamaki; Eiichi Shiba; Shinzaburo Noguchi
Journal:  J Cancer Res Clin Oncol       Date:  2004-02-24       Impact factor: 4.553

View more
  26 in total

1.  Diagnostic and prognostic correlates of preoperative FDG PET for breast cancer.

Authors:  Vincent Vinh-Hung; Hendrik Everaert; Jan Lamote; Mia Voordeckers; Hilde van Parijs; Marian Vanhoeij; Guy Verfaillie; Christel Fontaine; Hansjoerg Vees; Osman Ratib; Georges Vlastos; Mark De Ridder
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-07-10       Impact factor: 9.236

Review 2.  Present and future role of FDG-PET/CT imaging in the management of breast cancer.

Authors:  Kazuhiro Kitajima; Yasuo Miyoshi
Journal:  Jpn J Radiol       Date:  2016-01-05       Impact factor: 2.374

3.  Molecular mechanism underlying the detection of colorectal cancer by 18F-2-fluoro-2-deoxy-D-glucose positron emission tomography.

Authors:  Kunihiko Izuishi; Yuka Yamamoto; Takanori Sano; Ryusuke Takebayashi; Yoshihiro Nishiyama; Hirohito Mori; Tsutomu Masaki; Asahiro Morishita; Yasuyuki Suzuki
Journal:  J Gastrointest Surg       Date:  2011-11-08       Impact factor: 3.452

4.  Association between ¹⁸F-FDG uptake and molecular subtype of breast cancer.

Authors:  Kazuhiro Kitajima; Kazuhito Fukushima; Yasuo Miyoshi; Arisa Nishimukai; Seiichi Hirota; Yoko Igarashi; Takayuki Katsuura; Kaoru Maruyama; Shozo Hirota
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-05-07       Impact factor: 9.236

5.  The Prognostic Value of (18)F-FDG PET/CT for Early Recurrence in Operable Breast Cancer: Comparison with TNM Stage.

Authors:  Joo Hyun O; Woo Hee Choi; Eun Ji Han; Eun-Kyoung Choi; Byung Joo Chae; Yong-Gyu Park; Sung Hoon Kim
Journal:  Nucl Med Mol Imaging       Date:  2013-09-13

6.  Prognostic Significance of Metabolic Tumor Volume Measured by (18)F-FDG PET/CT in Operable Primary Breast Cancer.

Authors:  Jahae Kim; Su Woong Yoo; Sae-Ryung Kang; Sang-Geon Cho; Jong-Ryool Oh; Ari Chong; Jung-Joon Min; Hee-Seung Bom; Jung-Han Yoon; Ho-Chun Song
Journal:  Nucl Med Mol Imaging       Date:  2012-08-25

7.  Dual-Time 18F-FDG PET/CT Imaging in Initial Locoregional Staging of Breast Carcinoma: Comparison with Conventional Imaging and Pathological Prognostic Factors.

Authors:  Aynur Ozen; Serdar Altinay; Ozgul Ekmekcioglu; Ramazan Albayrak; Ali Muhammedoglu; Hakan Yigitbas; Eylem Bastug; Atilla Celik
Journal:  Indian J Surg       Date:  2016-04-23       Impact factor: 0.656

8.  Added value of semi-quantitative breast-specific gamma imaging in the work-up of suspicious breast lesions compared to mammography, ultrasound and 3-T MRI.

Authors:  T Meissnitzer; A Seymer; P Keinrath; J Holzmannhofer; C Pirich; K Hergan; M W Meissnitzer
Journal:  Br J Radiol       Date:  2015-04-17       Impact factor: 3.039

9.  Factors Associated with (18)F-Fluorodeoxyglucose Uptake in T1 and T2 Invasive Ductal Carcinoma of the Breast.

Authors:  So Jung Kim; Seong-Jang Kim; In Joo Kim; Kyoungjune Pak; Bum Soo Kim; Seunghyeon Shin
Journal:  Nucl Med Mol Imaging       Date:  2016-03-23

10.  The Relationship Between Estrogen Receptor, Progesterone Receptor and Human Epidermal Growth Factor Receptor 2 Expression of Breast Cancer and the Retention Index in Dual Phase (18)F-FDG PET/CT.

Authors:  Hansol Moon; Woo Chul Noh; Hyun-Ah Kim; Eun-Kyu Kim; Ko Woon Park; Seung Sook Lee; Joon Ho Choi; Kyung Woo Han; Byung Hyun Byun; Ilhan Lim; Byung Il Kim; Chang Woon Choi; Sang Moo Lim
Journal:  Nucl Med Mol Imaging       Date:  2016-04-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.